Published in Lancet on November 29, 2003
Liver cirrhosis. Lancet (2008) 6.11
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Recommendations for the use of albumin and immunoglobulins. Blood Transfus (2009) 1.75
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl (2011) 1.44
Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care (2012) 1.30
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci (2007) 1.18
Regulatory processes interacting to maintain hepatic blood flow constancy: Vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res (2007) 1.10
Kidneys in chronic liver diseases. World J Gastroenterol (2012) 1.10
The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant (2005) 1.02
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol (2015) 0.99
Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci (2011) 0.97
Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol (2014) 0.95
Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol (2012) 0.94
Hepatorenal syndrome. World J Gastroenterol (2012) 0.93
Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J Gastroenterol (2008) 0.92
Anesthetic Considerations in Hepatectomies under Hepatic Vascular Control. HPB Surg (2012) 0.91
Liver cirrhosis and arterial hypertension. World J Gastroenterol (2006) 0.90
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol (2012) 0.86
Management of acute renal failure. Postgrad Med J (2006) 0.86
Scoring systems for predicting mortality after liver transplantation. PLoS One (2014) 0.85
Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol (2015) 0.84
Updates on Hepato-Renal Syndrome. J Anesth Clin Res (2013) 0.83
Bile duct ligation in rats: a reliable model of hepatorenal syndrome? World J Gastroenterol (2009) 0.83
A new look at renal dysfunction in the cirrhotic patient. Crit Care (2012) 0.83
Clinical manifestations of portal hypertension. Int J Hepatol (2012) 0.81
Dosing of ceftriaxone and outcomes after spontaneous bacterial peritonitis. F1000Res (2014) 0.80
Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med (2012) 0.79
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol (2011) 0.79
Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center. Hepatol Int (2010) 0.79
Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int (2014) 0.79
Acute renal failure and the critically ill surgical patient. Ann R Coll Surg Engl (2007) 0.78
Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci (2013) 0.78
Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract (2015) 0.78
Systemic abnormalities in liver disease. World J Gastroenterol (2009) 0.78
Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepat Med (2011) 0.78
Advances in liver transplantation allocation systems. World J Gastroenterol (2016) 0.78
Corticomedullary differentiation on T1-Weighted MRI: comparison between cirrhotic and noncirrhotic patients. J Magn Reson Imaging (2011) 0.77
A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome. Dig Dis Sci (2014) 0.77
Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol (2015) 0.77
Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol (2010) 0.76
Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis. World J Gastroenterol (2014) 0.76
Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World J Gastroenterol (2015) 0.76
The factors affecting bone density in cirrhosis. Hepat Mon (2015) 0.76
Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis. Electron Physician (2015) 0.75
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron (2015) 0.75
The extrahepatic consequences of cirrhosis. MedGenMed (2006) 0.75
Tumor necrosis factor-alpha-induced reduction of glomerular filtration rate in rats with fulminant hepatic failure. Lab Invest (2014) 0.75
Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. World J Gastroenterol (2016) 0.75
Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract (2015) 0.75
AKI-CLIF-SOFA: a novel prognostic score for critically ill cirrhotic patients with acute kidney injury. Aging (Albany NY) (2017) 0.75
Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. MedGenMed (2004) 0.75
The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2015) 0.75
Management of cirrhotic ascites. Ther Adv Chronic Dis (2015) 0.75
Outcomes of liver transplantation in patients with hepatorenal syndrome. World J Hepatol (2016) 0.75
Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Semin Intervent Radiol (2015) 0.75
Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. Clin Biochem Rev (2016) 0.75
Hepatorenal syndrome. World J Gastroenterol (2007) 0.75
Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011. Int J Nephrol (2016) 0.75
Viral-host interaction in kidney reveals strategies to escape host immunity and persistently shed virus to the urine. Oncotarget (2016) 0.75
Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y) (2006) 0.75
Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol (2015) 0.75
Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol (2006) 0.75
Estimated Glomerular Filtration Rate (eGFR) Values as Predictor of Renal Insufficiency in Advanced Stages of Liver Diseases with Different Etiology. Med Arch (2014) 0.75
Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis (2016) 0.75
Management of hepatorenal syndrome. World J Nephrol (2015) 0.75
Portal hypertension--old problem, new therapeutic solutions. Wien Med Wochenschr (2006) 0.75
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg (2008) 5.94
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (2003) 3.66
Role of a research ethics committee in follow-up and publication of results. Lancet (2003) 3.61
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology (2010) 3.45
A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol (2013) 3.41
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 2.83
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology (2002) 2.34
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol (2012) 2.20
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol (2013) 2.11
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology (2012) 2.03
[A secure job for ever]. Med Clin (Barc) (2003) 2.01
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol (2009) 1.96
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol (2003) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol (2011) 1.87
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology (2006) 1.85
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J (2011) 1.79
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology (2005) 1.77
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology (2006) 1.64
Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology (2010) 1.61
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med (2010) 1.60
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology (2004) 1.56
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J Hepatol (2013) 1.55
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology (2006) 1.54
Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut (2012) 1.53
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology (2005) 1.53
Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology (2008) 1.51
Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut (2012) 1.51
Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J (2006) 1.50
[Organization and functioning model of biomedical research structures. Situation and future challenges]. Med Clin (Barc) (2008) 1.46
Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology (2006) 1.41
[Deaths by a medical resident. Could they have been avoided?]. Med Clin (Barc) (2003) 1.38
5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol (2010) 1.36
Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology (2002) 1.35
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. J Hepatol (2005) 1.34
Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther (2007) 1.33
Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology (2010) 1.29
Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol (2004) 1.28
Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in cirrhosis? J Hepatol (2013) 1.27
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology (2013) 1.23
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology (2010) 1.21
Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology (2002) 1.20